This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Management of ocular surface disease

Management of ocular surface disease
Reviewed by Jonathan Chan

3 February 2023 | Jonathan Chan | EYE - Cornea, EYE - General
Share This

This is a retrospective study of patients with ocular surface disease (OSIDs) treated with IKERVIS in a single centre between 2016 to 2019 with at least six months follow-up. Clinical outcome was defined as successful (resolved or stable disease), active disease or drug intolerance. Four hundred and sixty-three patients were included with a mean age of 51.5 years, 59% female and mean follow-up time was 14.6 months. The common diagnosis was dry eye disease (DED) 69.5%, allergic eye disease (AED) 11.4%, and ocular mucous membrane pemphigoid/ Steven-Johnson syndrome (OMMP/SJS) 8.2%. Successful treatment was achieved in 74.1% of patients, 9.5% required further treatment and 16.4% reported drug intolerance. The efficacy of IKERVIS was best in DED - 82%, OMMP/SJS - 65.8% and post-keratoplasty - 50%. Drug intolerance was found in significant predictive factors which included age <70years, AED and OMMP/SJS groups of patients. AED and post-keratoplasty groups were most likely to require additional treatment compared to the DED group. The authors concluded that IKERVIS is a useful steroid-sparing agent topical treatment in OSIDs but drugs with better improved tolerance are needed in OSID patients.

Real-world experience of using cyclosporin-A 0.1% (CSA) in the management of ocular surface disease (OSIDs).
Desmukh R, Ting DSJ, Elsahn A, et al.
BRITISH JOURNAL OF OPHTHALMOLOGY
2022;106(8):1087-92.
Share This
CONTRIBUTOR
Jonathan Chan

Royal Hallamshire Hospital, Sheffield, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency